Side-Bars

Injection Technique Important
The User's Perspective on Injectables
The Shelf-Life of Injectables
WHO Eligibility Criteria: Differences Between Progestin-Only Injectables and Combined Oral Contraceptives
New Injection Systems to Help Prevent Infection
Five Basic Steps of Infection Prevention: Do's and Don'ts

Injection Technique Important

Careful injection technique ensures that the full dose is absorbed at the right rate and thus is fully effective.
  • With DMPA, providers need to shake vials to dissolve any sediment at the bottom, but they should not shake so vigorously that the liquid becomes frothy and difficult to draw into the syringe.
  • With NET EN, warming vials to body temperature thins the viscous solution and makes it easier to draw completely into the syringe (333).
  • With all injectables, the injection should be given in muscle because absorption may be too slow if the provider injects into fat (85). In contrast, massaging the injection site accelerates absorption and thus also should be avoided (333).
Return to Chapter 3.1


The User's Perspective on Injectables

Women's attitudes toward progestin-only injectables largely reflect their feelings about the privacy and convenience of injections and menstrual bleeding disruptions. These feelings in turn reflect not only the attributes and physiological effects of the method but also women's knowledge and understanding of the method, personal needs, contraceptive experience, partners' attitudes, and cultural norms. Family planning providers can better counsel and advise clients if they are aware of these differing attitudes and physiological responses. Similarly, communication programs must understand people's attitudes and reactions in order to devise effective messages.

The New User

Women choose injectables because:
  • They want a highly effective, reversible contraceptive.
  • They want a long-acting method but not one that lasts for years. They do not want to take a pill every day.
  • They have faith in the effectiveness of injectable medication because of the well-known efficacy of injectable antibiotics and the success of campaigns with injected penicillin, such as yaws eradication.
  • They may like amenorrhea, especially if they usually have heavy menstrual flows and cramping.
  • They want a contraceptive that can be used privately, a method that can be obtained quickly at the clinic and requires no supplies around the house.
  • They want a method that does not require action at the time of sexual relations.
  • They want a reliable and safe method that can be used during breastfeeding.
  • They have talked with friends or relatives who are using injectables satisfactorily (14, 20, 23, 46, 54, 62, 95, 146, 160, 162, 198, 217, 350).
In interviews women in places as different as Bangladesh and the US mention many of these advantages (14, 62):

Bangladesh
"...with pills you have to have a dose every day, and there's a chance of your forgetting. With injectables, you don't have such worries. The field worker keeps track of when I'm supposed to take my shots and comes and gives them to me herself. And since it's a woman who's giving me the shots, my family doesn't object.

"One of my husband's relatives once said to me, `Injectables are good. I've been using them for three years. Come with me and you'll be able to get an injection, too. There won't be any trouble.' So I talked to my husband and after he agreed, I began using injectables. Many others have followed me. Even my sister-in-law uses injectables now.

"I started using injectables after I had two children in quick succession."

United States
"I got pregnant when I was 13 and had my baby when I was 14. I did not use any birth control when I got pregnant. Depo is much easier than taking the Pill every day. I'm not good at remembering to take pills.

"I decided to use the Depo shot because it was very easy. You just come back every three months. I didn't decide to take the Pill because I am on medication for seizures. I thought I would forget to take the pills.

"I was a poor pill taker. I thought barrier methods were inconvenient and messy."

The Continuing User

Users' attitudes toward injectables are reflected in discontinuation rates. The most common reason for stopping injectables is side effects. In a WHO trial of DMPA, for example, half of users discontinued after one year: about one-third stopped because of side effects—for example, menstrual disruption, headaches, dizziness, or weight gain—and the rest stopped for personal reasons or were lost to follow-up (342).

Women's attitudes toward side effects, particularly menstrual disruption, are varied and complex (111, 115, 278, 324, 327). Irregular bleeding is inconvenient for many women who do not have sexual relations while menstruating (327). Muslim women often discontinue injectables because their religion forbids them to pray, fast, read from the Koran, or have sexual relations during vaginal bleeding. Amenorrhea may make some women think that they are pregnant or that a drug powerful enough to take away monthly bleeding is unhealthy in other ways. Many people have the false idea that, if a woman does not menstruate, poisonous blood collects in her body (327).

Such attitudes are not universal. Many users in Jamaica, Indonesia, and Thailand, for example, accept menstrual disruption (115). For many users the benefits of effective contraception clearly outweigh the disadvantages of side effects. A Bangladeshi woman commented:

"We are very poor. So we won't be able to survive if we have too many children. That's why I use Depo, even though it does give me a little trouble (62)."

For some women amenorrhea and weight gain are advantages of injectables. A US woman using DMPA commented:

"I became amenorrheic after one month of use. I love that. I haven't had periods for five years and it has been great. I worried the first month that I might be pregnant. I talked with my doctor about it and was reassured. Before Depo I had dysmenorrhea [painful menstruation] and now it has disappeared--no bloating, cramps, or weight gain (275)."

Women in Egypt, Nepal, the Philippines, Sierra Leone, and Thailand have reported that they like weight gain experienced with progestin-only injectables (11, 117, 241, 270, 298).

Counseling can help women who choose injectables to adapt to the side effects. Counseling may be so important to clients, in fact, that they are willing to pay for it. In the 1970s the McCormick Family Planning Program, which pioneered use of DMPA in Thailand, offered the injectable for a small fee, while the public family planning program in the same area offered free services. Program staff observed that many DMPA users preferred to pay the small fee because of the good counseling that they received with each injection in the McCormick program (20).

*****************************************************************

Survey of Service Providers

Service providers in 10 countries responded to a Population Reports questionnaire asking about their perception of injectables, their clients' perceptions, difficulties and benefits of providing injectable services, medical eligibility requirements for the use of injectables, and lessons learned. Their answers have been used extensively in this report, particularly in "The User's Perspective."

Bangladesh:Sabera Rahman, Mohammadpur Fertility Services and Training Centre
Guatemala:Roberto Santiso Galvez, Asociación Pro Bienestar de la Familia de Guatemala (APROFAM)
Hong Kong:Margaret Kwan, Family Planning Association of Hong Kong
Kenya:C.N. Kamau and Margaret N. Thuo, Family Planning Association of Kenya
Madagascar:Manitra Andriamasinoro, Fianakaviana Sambatra
Philippines:Jovencia B. Quintong, Family Planning Service, Department of Health
Sierra Leone:Willie E. Taylor, Planned Parenthood Association of Sierra Leone
Sri Lanka:Sriani Basnayake, Family Planning Association of Sri Lanka
Sudan:Ahmed M. Youssif, Sudan Family Planning Association
Thailand:Sombhong Pattawichaiporn, Planned Parenthood Association of Thailand
Interviews with users of injectables in Bangladesh were conducted by Achintya Das Gupta, Yasmin Khan, Marufa Khanam, Khadija Bilkis, Rashida Sultana, and Tawfique N. Hamid, all staff members of the Bangladesh office of Johns Hopkins Population Communication Services.



The Shelf-Life of Injectables

Confusion arises over a difference in the labeled shelf-life of DMPA: DMPA made by Upjohn's Belgian subsidiary is labeled with a shelf-life of five years; DMPA made by Upjohn in the US is currently labeled for three years of shelf-life.

The US and Belgian products are identical, however. When the US FDA first approved DMPA in 1992, the stability of DMPA manufactured in the US had been tested for just two years. Upjohn since then has continued to test DMPA, and the US FDA is gradually extending the labeled shelf-life of the US product every six months. It will reach five years in April 1997 (55). The labeled shelf-life of NET EN and Mesigyna is five years. The labeled shelf-life of Cyclofem is being extended to four years in Indonesia and to three years in Mexico (173).

All injectables should be stored at room temperature, away from excessive heat and moisture. DMPA may be stored at temperatures from 15º C to 30º C (60º F to 86º F) (223, 312).



WHO Eligibility Criteria:
Differences Between Progestin-Only Injectables and Combined Oral Contraceptives

The recommendations of eligibility criteria for progestin-only injectables and combined oral contraceptives (OCs), formulated by the WHO scientific working group on improving access to quality care in family planning, are similar for most conditions. For some, however, the estrogen in combined OCs makes a difference. Thus the working group made important distinctions between DMPA/NET EN and combined OCs for women with the following conditions:


Condition
Categorya
DMPA/NET ENOCs
Breastfeeding
   Six weeks to six months after delivery

1

3
Postpartum
   Three weeks or less and not breastfeeding

1

3
Smoking and age greater than 35
   Light (fewer than 20 cigarettes)
   Heavy (20 cigarettes or more)

1
1

3
4
History of hypertension23
Deep venous thrombosis/pulmonary embolismb14
Complicated valvular heart disease14
Recurrent severe headaches with focal neurologic symptomsc2d/3e 4
Sickle-cell disease13
a For description of categories 1-4, see Chapter 9.3 Eligibility Criteria.
b Women with varicose veins may use either DMPA/NET EN or combined OCs.
c That is, severe headaches that cause trouble seeing, speaking, or moving.
d For initiation of the method.
e For continuation of method if condition develops during use.



New injection Systems to Help Prevent Infection

New, one-use delivery systems, UniJect™ and autodestruct syringes, may simplify infection prevention. The unique feature of UniJect is a plastic blister that is filled with the medication. The provider presses the blister to deliver the medication through the attached needle. UniJect has a one-way valve between the needle and the blister that prevents it from being refilled and reused, and it can be burned without generating toxic fumes. The Program for Appropriate Technology in Health (PATH) developed UniJect with funding from USAID. WHO is testing UniJect with Cyclofem in Brazil and several other countries (109, 173, 204, 257). Autodestruct syringes have a metal clip in the syringe that locks the plunger in place after one injection to prevent refilling (28, 173, 258). Autodestruct syringes cost about $0.09 compared with $0.05 for conventional disposable syringes (293, 344). The cost of UniJect will be comparable to the cost of autodestruct syringes (361).


Five Basic Steps of Infection Prevention:
Do's and Don'ts

CLEANING HANDS
---------------------
STERILIZATION
Reusable needles and syringes should be sterilized by autoclaving (steam sterilization) or dry heat.

Steam sterilization:
121ºC (250ºF) at 106 kPa (15 lbs/in2 pressure for 20 minutes for unwrapped needles and syringes, 30 minutes for wrapped items. Allow all items to dry thoroughly before removing.

Dry heat:
(glass or metal items only)
160ºC (320ºF) for 2 hours (total cycle time for heating up and cooling off is 3 to 3-1/2 hours). Needles should be sterilized at precisely 160ºC (320ºF) because higher temperatures can dull sharp edges.

Storage:
Unwrapped needles and syringes exposed to the air must be used immediately. In dry sterile containers they may be stored for no longer than one week. Wrapped needles and syringes can be stored for one week if the package remains dry and intact and for one month if sealed in a plastic bag.

---------------------
HIGH-LEVEL DISINFECTION

If sterilization is not possible, reusable needles and syringes should be high-level disinfected by boiling or steaming for 20 minutes and then allowed to dry. They can be used immediately or stored for up to one week in a clean, high-level disinfection of needles and syringes should be avoided.

A high-level disinfected container is prepared by boiling, if it is small enough, or soaking for 20 minutes in a plastic container filled with 0.5% chlorine solution. The chlorine solution can then be transferred to another container and reused. The container should be rinsed thoroughly with boiled water and allowed to air dry.

Sources: Lubis et al. 1995 (188), POGI et al. 1995 (132), Schaefer (273), Tietjen et al. 1992 (305), WHO 1990 (333).

1 DO wash hands before each injection. This is one of the most important steps in infection prevention.
PREPARING THE INJECTION SITE
2 DO make sure the site of the injection is clean and disinfected.
DO swab the site with a new piece of cotton for each client.
DO wipe from the injection site outwards in a circular motion.
DO NOT use the same piece of cotton repeatedly to clean the injection sites of several clients.
USING STERILE NEEDLES AND EQUIPMENT
3 DO use a new disposable needle and syringe for each injection. OR
DO make sure that reusable needles and syringes are sterilized or high-level disinfected before each use.
DO use single-dose vials of injectable. If using multidose vials, keep the unused portions sterile.
DO NOT use the same needle and syringe for more than one client without processing the equipment.
DO NOT change the needle but still use the same syringe for several clients.
DO NOT leave a needle in the stopper of a multidose vial to withdraw the fluid.
PROCESSING USED INJECTION EQUIPMENT
4 Processing Disposable Equipment
DO decontaminate disposable needles and syringes by flushing them with 0.5% chlorine solution 3 times or soaking them in the chlorine solution for 10 minutes.

DO dispose of disposable needles and syringes by placing them in a puncture-proof container and then burning and/or burying the container when three-quarters full.

Processing Reusable Equipment
DO process reusable needles and syringes appropriately:
  1. Decontamination in 0.5% chlorine solution for 10 minutes.
  2. Cleaning with soap and water and rinsing 3 times with clean water.
  3. Sterilization or high-level disinfection (see column to the right)
DO sterilize or high-level disinfect containers in which reusable needles and syringes are stored.
DO NOT put disposable needles in the trash, even after they have been decontaminated.

DO NOT recap disposable needles before disposal.

DO NOT bend or break needles before disposal.

DO NOT high-level disinfect or sterilize equipment without decontaminating and cleaning it first.

DO NOT clean needles and syringes without taking them apart.

DO NOT use needles and syringes that have been cleaned only with alcohol or other disinfectant or antiseptic.

DO NOT reuse disposable needles and syringes. If they must be reused, it is recommended that only the syringe be reprocessed and reused, after decontaminating both the needle and syringe.

DO NOT store sterilized or high-level disinfected needles and syringes in a container that has not been sterilized or high-level disinfected.

PREPARING THE INJECTION SITE
5 DO dispose of waste such as cotton and gauze that are contaminated with blood or other body fluids in a leak-proof container with a lid or in a plastic bag.
DO NOT throw contaminated materials into the general trash.

Previous | Next
Top of Page | Table of Contents


111 Market Place, Suite 310, Baltimore, MD 21202, USA
Phone: (410) 659.6300/Fax: (410) 659.6266/E-mail: Poprepts@jhuccp.org

Population Reports